Phase II: Colorectal Cancer

Study: Safety/Efficacy Study of Imprime PGG® with Cetuximab in Patients with Recurrent/Progressive Colorectal Carcinoma

ClinicalTrials.gov Id: NCT00545545

Biothera has completed a dual-arm Phase Ib/II trial with 32 second- and third-line metastatic colorectal cancer patients to evaluate the safety and efficacy of Imprime PGG® and cetuximab (Erbitux®) with and without irinotecan, a chemotherapy drug.

Status: Study Completed.

Locations: Asia Multicenter

Study: Efficacy and Safety Study of Imprime PGG with Cetuximab in Subjects with Stage IV KRAS-Mutated Colorectal Cancer

ClinicalTrials.gov Id: NCT00912327

Biothera has completed enrollment in a Phase II clinical trial in stage IV KRAS-mutated colorectal cancer patients with Imprime PGG® in combination with cetuximab (Erbitux®). The open-label trial may enroll up to 56 patients.

Status: The trial is fully enrolled.